logo
Share SHARE
FONT-SIZE Plus   Neg

Biogen Idec Sells BENLYSTA Royalty Rights To DRI Capital Managed Fund

Biogen Idec (BIIB) has sold to a DRI Capital managed fund its royalty and other rights pertaining to BENLYSTA to which Biogen Idec is entitled pursuant to a license deal with Human Genome Sciences Inc. (HGSI) and Glaxo Group Ltd. According to the agreement between Biogen Idec and DRI, Human Genome Sciences and Glaxo Group Ltd. would make royalty payments directly to DRI instead of to Biogen Idec. In turn, DRI would pay Biogen Idec a multiple of certain of the royalties received for the period covering October 2011 to September 2014.

Following that period, DRI would retain the royalty payments from BENLYSTA sales, with certain exceptions, including a one-time contingency payment that could be triggered if the cumulative royalties to DRI exceed an agreed amount. The initial payment by DRI to Biogen Idec, covering the royalty period from October 1, 2011 to March 30, 2012 is nearly $18.3 million and would be recognized into income as a gain in the third quarter.

BENLYSTA was approved by the US Food and Drug Administration in March 2011 and by the European Medicines Agency in July 2011 to treat systemic lupus erythematosus.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Belgian brewer Anheuser-Busch InBev NV or AB InBev on Thursday said it is acquiring Hiball Inc., a San Francisco-based maker of organic energy drinks and carbonated juices and water. The company did not disclose the terms of the deal. Denver, Colorado based low-cost carrier Frontier Airlines will expand its services to 21 cities. The airline which serves 80 cities in the U.S., Mexico and the Dominican Republic is planning to add 85 new routes. Abbott Laboratories (ABT) reported a profit for the second-quarter 2017 declined about 54.1 percent from last year, hurt by higher costs. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. Abbott raised its full-year 2017 earnings per share guidance range.
comments powered by Disqus
Follow RTT